ストックスクリーナーアプリを入手
2.66
1.12%
-0.03
アフターアワーズ：
2.65
-0.01
-0.38%
Protalix BioTherapeutics Inc. (PLX) 最新ニュース
Protalix BioTherapeutics (NYSE:PLX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Insider’s View: Deciphering Protalix BioTherapeutics Inc (PLX)’s Financial Health Through Ratios - The Dwinnex
Was Protalix BioTherapeutics Inc (PLX)’s session last reading good? - US Post News
Research Analysts Set Expectations for PLX FY2025 Earnings - Defense World
What is HC Wainwright’s Forecast for PLX FY2024 Earnings? - Defense World
Zacks Small Cap Has Negative Outlook for PLX FY2025 Earnings - MarketBeat
Equities Analysts Issue Forecasts for PLX FY2024 Earnings - MarketBeat
H.C. Wainwright lifts Protalix stock target to $15, maintains buy - MSN
Research Analysts Issue Forecasts for PLX Q1 Earnings - Defense World
Protalix Biotherapeutics gains momentum in the rare disease space: analysts - Proactive Investors USA
Perhaps timely catching Protalix BioTherapeutics Inc (PLX) would be a good idea - SETE News
What is HC Wainwright's Forecast for PLX Q1 Earnings? - MarketBeat
Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference - WV News
Protalix BioTherapeutics (NYSE:PLX) Given New $15.00 Price Target at HC Wainwright - Defense World
Protalix BioTherapeutics (NYSE:PLX) Stock Rating Lowered by StockNews.com - Defense World
PLX: Revisiting the Thesis - Research Tree
Will Protalix remain independent? - גלובס
Investor Network: Protalix BioTherapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Protalix BioTherapeutics (NYSE:PLX) Rating Lowered to Buy at StockNews.com - Defense World
Protalix BioTherapeutics (NYSE:PLX) Lowered to "Buy" Rating by StockNews.com - MarketBeat
Protalix BioTherapeutics Outlines Strategic Roadmap for 2025 - Proactive financial news
Jane Street Group LLC Has $47,000 Position in Protalix BioTherapeutics, Inc. (NYSE:PLX) - Defense World
Hypophosphatasia Treatment Market reached US$ 841.9 million - openPR
US Penny Stocks: Arbe Robotics And 2 More Promising Picks - Simply Wall St
Who's Going to Buy This Orphan Drugmaker? - AOL
PLX stock touches 52-week high at $2.17 amid robust gains - Investing.com
Head-To-Head Analysis: Humacyte (NASDAQ:HUMA) & Protalix BioTherapeutics (NYSE:PLX) - Defense World
Sanctuary Advisors LLC Acquires New Shares in Protalix BioTherapeutics, Inc. (NYSE:PLX) - Defense World
MB Sounding Board: Dual Listed Companies and Associated Challenges - Mayer Brown
Protalix Achieves Key Milestones and Remains Debt-Free - TipRanks
Protalix BioTherapeutics Hits Key Milestones: Debt-Free Status, Revenue Growth & Clinical Progress - StockTitan
Protalix BioTherapeutics Issues 2025 Letter to Stockholders - PR Newswire
Fabry Disease Treatment Market Growth in Future Scope 2024-2031 - openPR
Protalix BioTherapeutics' Phase 1 Data Bolsters Gout Aspirations (Rating Upgrade) - Seeking Alpha
Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - The Eastern Progress Online
Less frequent Elfabrio ERT regimen for Fabry up for EU approval –... - Fabry Disease News
EMA validates Chiesi and Protalix’s dose variation for Fabry disease - Yahoo Finance
EMA validates Chiesi/Protalix’s submission of pegunigalsidase alfa - Pharmaceutical Technology
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa – Company AnnouncementFT.com - Financial Times
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa - PR Newswire
Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024 - The Eastern Progress Online
Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results - The Eastern Progress Online
Botanical and Plant-Derived Drugs Market to grow by USD 20.93 Billion (2024-2028), driven by government initiatives, with AI powering market evolutionTechnavio - Yahoo Finance
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
PLX: Self-Sustaining Rise to Lead in Renal Rare Disease - Yahoo Finance
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2024 Earnings Call Transcript - Insider Monkey
Protalix BioTherapeutics Inc. (PLX) Quarterly 10-Q Report - Quartzy
Protalix: Q3 Earnings Snapshot - New Haven Register
Protalix BioTherapeutics Inc (PLX) Q3 2024 Earnings Call Highlights: Revenue Surge and ... - Yahoo Finance
Protalix BioTherapeutics Reports Strong Q3 2024 Results - TipRanks
Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results - citybiz
1.03%
大文字化:
|
ボリューム (24 時間):